Literature DB >> 22879043

Metabolic network analysis of DB1 melanoma cells: how much energy is derived from aerobic glycolysis?

A A Shestov1, A Mancuso2,3, D B Leeper4, J D Glickson5.   

Abstract

A network model has been developed for analysis of tumor glucose metabolism from (13)C MRS isotope exchange kinetic data. Data were obtained from DB1 melanoma cells grown on polystyrene microcarrier beads contained in a 20-mm diameter perfusion chamber in a 9.4 T Varian NMR spectrometer; the cells were perfused with 26 mM [1,6-(13)C(2)]glucose under normoxic conditions and 37°C and monitored by (13)C NMR spectroscopy for 6 h. The model consists of ∼150 differential equations in the cumomer formalism describing glucose and lactate transport, glycolysis, TCA cycle, pyruvate cycling, the pentose shunt, lactate dehydrogenase, the malate-aspartate and glycerophosphate shuttles, and various anaplerotic pathways. The rate of oxygen consumption (CMRO(2)) was measured polarographically by monitoring differences in pO(2). The model was validated by excellent agreement between model predicted and experimentally measured values of CMRO(2) and glutamate pool size. Assuming a P/O ratio of 2.5 for NADH and 1.5 for FADH2, ATP production was estimated as 46% glycolytic and 54% mitochondrial based on average values of CMRO(2) and glycolytic flux (two experiments).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22879043     DOI: 10.1007/978-1-4614-4989-8_37

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

1.  Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan.

Authors:  Kavindra Nath; David S Nelson; Daniel F Heitjan; Rong Zhou; Dennis B Leeper; Jerry D Glickson
Journal:  NMR Biomed       Date:  2015-03       Impact factor: 4.044

2.  The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters.

Authors:  Bethany Nancolas; Lili Guo; Rong Zhou; Kavindra Nath; David S Nelson; Dennis B Leeper; Ian A Blair; Jerry D Glickson; Andrew P Halestrap
Journal:  Biochem J       Date:  2016-02-01       Impact factor: 3.857

3.  MicroRNA-33b inhibits cell proliferation and glycolysis by targeting hypoxia-inducible factor-1α in malignant melanoma.

Authors:  Yue Zhao; Cuiling Wu; Lina Li
Journal:  Exp Ther Med       Date:  2017-06-28       Impact factor: 2.447

4.  Hypoxia potentiates the capacity of melanoma cells to evade cisplatin and doxorubicin cytotoxicity via glycolytic shift.

Authors:  Ming Zhuo; Falih M Gorgun; Douglas S Tyler; Ella W Englander
Journal:  FEBS Open Bio       Date:  2020-04-14       Impact factor: 2.693

5.  Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step.

Authors:  Alexander A Shestov; Xiaojing Liu; Zheng Ser; Ahmad A Cluntun; Yin P Hung; Lei Huang; Dongsung Kim; Anne Le; Gary Yellen; John G Albeck; Jason W Locasale
Journal:  Elife       Date:  2014-07-09       Impact factor: 8.140

6.  (13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism.

Authors:  Alexander A Shestov; Seung-Cheol Lee; Kavindra Nath; Lili Guo; David S Nelson; Jeffrey C Roman; Dennis B Leeper; Mariusz A Wasik; Ian A Blair; Jerry D Glickson
Journal:  Front Oncol       Date:  2016-06-15       Impact factor: 6.244

7.  Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice.

Authors:  Kavindra Nath; David S Nelson; Mary E Putt; Dennis B Leeper; Bradley Garman; Katherine L Nathanson; Jerry D Glickson
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.